Osteogenesis Imperfecta (OI) Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

The Osteogenesis Imperfecta (OI) market was valued at approximately USD 30 million in the 7MM (2023) and is projected to grow at a significant CAGR during the forecast period (2025–2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Osteogenesis Imperfecta landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Osteogenesis Imperfecta market is increasingly guided by the development of novel bone-forming agents and gene therapies. The market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs and the expected market launch of emerging therapies like Setrusumab (UX143).

DelveInsight’s report, “Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast- 2034,” provides a comprehensive analysis of the Osteogenesis Imperfecta landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Osteogenesis Imperfecta market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Osteogenesis Imperfecta market outlook, drug uptake, treatment scenario and epidemiology trends, visit; Osteogenesis Imperfecta Market Forecast

Some of the key facts of the Osteogenesis Imperfecta Market Report:

• Key Osteogenesis Imperfecta Companies: Ultragenyx Pharmaceutical, Mereo BioPharma, Amgen, Merck & Co, Sanofi, Novartis, BioSenic SA, OrthoPediatrics Corp, Ascendis Pharma A/S, Teva Pharmaceutical Industries, Castle Creek Biosciences, Mesoblast, and others.
• Key Osteogenesis Imperfecta Therapies: Setrusumab (UX143), Fresolimumab, Bisphosphonates (Alendronate, Risedronate, Pamidronate, Zoledronic acid), Denosumab, Teriparatide, BPS-804, and others.
• The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing diagnosis rates and the introduction of targeted therapies during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the market dynamics.

Osteogenesis Imperfecta Overview

Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a group of rare genetic disorders that mainly affect the development of bones. It is caused by defects in the production of type I collagen, a protein that is critical for bone strength. The condition ranges in severity from mild forms with few fractures to severe forms that can be lethal in infancy. Osteogenesis Imperfecta is often diagnosed through a combination of clinical evaluation, family history, and genetic testing for mutations in the COL1A1 or COL1A2 genes. Common symptoms include frequent fractures, blue sclerae, short stature, hearing loss, and dental abnormalities (dentinogenesis imperfecta).

Key Trends in Osteogenesis Imperfecta Therapeutics Market:

• Advancement in Monoclonal Antibodies: Increasing focus on sclerostin inhibitors like Setrusumab to improve bone density and strength.
• Gene Therapy Exploration: Investigation into cell and gene therapies to address the underlying genetic cause of Osteogenesis Imperfecta.
• Improved Diagnostic Imaging: Adoption of high-resolution 3D bone imaging to better assess bone quality and fracture risk.
• Pediatric Focus: Growing number of clinical trials specifically targeting pediatric populations to prevent deformities early in life.
• Novel Drug Delivery: Development of more convenient administration routes for bone-strengthening agents.

Osteogenesis Imperfecta Epidemiology

The Osteogenesis Imperfecta epidemiology section of the report provides a comprehensive analysis of the disease’s prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on key genetic subtypes such as COL1A1 and COL1A2 mutations. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Osteogenesis Imperfecta and plan targeted interventions, research, and treatment strategies.

Osteogenesis Imperfecta Epidemiology Segmentation:

The Osteogenesis Imperfecta market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Prevalent Cases of Osteogenesis Imperfecta
• Diagnosed Cases of Osteogenesis Imperfecta
• Gene-specific Cases of Osteogenesis Imperfecta
• Type-specific Cases of Osteogenesis Imperfecta
• Total Treated Cases of Osteogenesis Imperfecta

Download the report to understand which factors are driving Osteogenesis Imperfecta epidemiology trends @ Osteogenesis Imperfecta Epidemiology Forecast

Recent Development In The Osteogenesis Imperfecta Treatment Landscape:

• In September 2025, Amgen launched a next-generation bone anabolic therapy for Osteogenesis Imperfecta patients, focusing on increasing bone density and reducing fracture risk.
• In August 2025, Ultragenyx Pharmaceutical expanded its gene therapy trials targeting Osteogenesis Imperfecta types I and III, emphasizing long-term correction of collagen defects. Initial deployments report promising safety profiles and functional improvements.
• In July 2025, Pfizer introduced sclerostin-inhibitor treatments for severe Osteogenesis Imperfecta cases to enhance bone strength and prevent fractures.
• In June 2025, Novartis launched combination therapy studies addressing both bone fragility and pain management in OI patients. Pilot programs demonstrate enhanced mobility and reduced pain scores.
• In August 2025, Angitia Biopharmaceuticals announced plans for Phase 2 trials of AGA2115 (bispecific antibody) following positive Phase 1 data in healthy volunteers showing favorable safety, pharmacokinetics, and bone biomarkers.
• In November 2025, FDA granted Orphan Drug Designation to Medivir's MIV-711 (cathepsin K inhibitor) for OI treatment, providing development incentives.

Osteogenesis Imperfecta Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteogenesis Imperfecta market or expected to get launched during the study period. The analysis covers Osteogenesis Imperfecta market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteogenesis Imperfecta Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Osteogenesis Imperfecta Therapies and Key Companies

• Setrusumab (UX143): Ultragenyx Pharmaceutical / Mereo BioPharma
• Fresolimumab: Sanofi / Genzyme
• Denosumab (Prolia): Amgen
• Teriparatide (Forteo): Eli Lilly
• Bisphosphonates: Various Generic Manufacturers
• Cell Therapy Candidates: Castle Creek Biosciences / Mesoblast
• TP-05: Tarsus Pharmaceuticals, and others.

To know more about Osteogenesis Imperfecta companies working in the treatment market, visit @ Osteogenesis Imperfecta Clinical Trials and Therapeutic Assessment

Osteogenesis Imperfecta Market Drivers

• Increasing prevalence and diagnosis of genetic bone disorders.
• Robust pipeline of novel therapies targeting specific molecular pathways (e.g., sclerostin, TGF-beta).
• Rising awareness and advocacy for rare diseases improving patient identification.
• Government incentives for orphan drug development, such as market exclusivity and tax credits.
• Advances in genetic testing technologies facilitating earlier and more accurate diagnosis.

Osteogenesis Imperfecta Market Barriers

• High cost of emerging biologic therapies and gene treatments.
• Challenges in conducting clinical trials due to the small and heterogeneous patient population.
• Limited long-term safety data for new therapeutic classes in pediatric patients.
• Variability in insurance coverage and reimbursement for high-cost orphan drugs.
• Lack of approved therapies for certain severe or lethal subtypes of the disease.

Scope of the Osteogenesis Imperfecta Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Osteogenesis Imperfecta Companies: Ultragenyx Pharmaceutical, Mereo BioPharma, Amgen, Merck & Co, Sanofi, Novartis, BioSenic SA, OrthoPediatrics Corp, Ascendis Pharma A/S, Teva Pharmaceutical Industries, and others.
• Key Osteogenesis Imperfecta Therapies: Setrusumab (UX143), Fresolimumab, Denosumab, Teriparatide, Bisphosphonates, and others.
• Osteogenesis Imperfecta Therapeutic Assessment: Osteogenesis Imperfecta current marketed and emerging therapies
• Osteogenesis Imperfecta Market Dynamics: Osteogenesis Imperfecta market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Osteogenesis Imperfecta Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

Discover more about therapies set to grab major Osteogenesis Imperfecta market share @ Osteogenesis Imperfecta Treatment Market